Ketamine and Cannabis Interaction Safety: What to Know

Ketamine and cannabis are both central nervous system-active substances, and combining them can intensify dissociation, sedation, dizziness, and short-term changes in heart rate and blood pressure beyond what either produces alone. No published clinical trial has tested cannabis alongside the low, subanesthetic ketamine doses used in depression or pain protocols, so this guidance draws on the separate pharmacology of each drug and on regulatory warnings for esketamine (Spravato), the only ketamine-based medication with FDA approval, rather than on head-to-head interaction studies.

Low-dose ketamine is prescribed off-label for treatment-resistant depression and chronic pain outside of Spravato, and prescribers who use it typically screen for substance use, including cannabis, as part of standard intake. This article is educational and not a substitute for individualized medical advice; if you use cannabis in any form, including CBD-dominant or THC products, tell your prescriber before starting treatment and before any dosing session.

How Ketamine and Cannabis Can Interact

The main concern is additive central nervous system effects rather than a single sharp drug-drug reaction. Ketamine at subanesthetic doses commonly produces transient dissociation, dizziness, and mild sedation, effects covered in more detail in common side effects of low-dose ketamine. Cannabis, primarily through tetrahydrocannabinol (THC), the compound responsible for its psychoactive effects, produces overlapping effects: sedation, altered perception, and impaired coordination. According to the National Institute on Drug Abuse (NIDA), THC can raise heart rate for up to three hours after use, an effect that stacks on top of the temporary rise in heart rate and blood pressure ketamine produces during a dosing session, a pattern described in the site's pharmacokinetics overview.

Both drugs are also processed through overlapping liver metabolic pathways, which theoretically could alter how quickly one or both clear the bloodstream, though no published pharmacokinetic study has measured this at the doses used in maintenance ketamine protocols. Anyone with liver disease or on other enzyme-affecting medications should raise this with their prescriber; see ketamine-associated hepatotoxicity risk factors and liver function monitoring for related monitoring guidance.

What the Evidence Actually Shows, and What It Doesn't

The FDA-approved label for esketamine (Spravato), cleared in March 2019, requires patients to be monitored for at least two hours after each dose and advises caution when the medication is combined with other central nervous system depressants or psychoactive substances. That approval remains the only FDA-cleared ketamine-based treatment; low-dose intravenous, oral, and sublingual ketamine used for depression and pain remain off-label, meaning individual clinic protocols, not a single approved label, govern how cannabis use is handled.

Most ketamine clinics address cannabis use during intake as part of ketamine therapy contraindications and screening rather than through an automatic exclusion. Recreational or heavy cannabis use, active substance use disorder, or unstable psychiatric symptoms are more likely to raise concerns than occasional or medically supervised use, but policies vary by clinic, and there is no single evidence-based cutoff. Because dissociation and anxiety are known ketamine side effects, and cannabis has been separately linked to anxiety and psychotic-like symptoms in vulnerable people, prescribers weigh a patient's psychiatric history and reaction to each substance individually. Questions about how repeated substance exposure affects treatment durability connect to broader ketamine tolerance and long-term use considerations, and to how dissociation is tracked over a maintenance course through cognitive effects of repeated low-dose ketamine neuropsychological assessment.